185 related articles for article (PubMed ID: 7481823)
1. Self-release of CLIP in peptide loading of HLA-DR molecules.
Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
[TBL] [Abstract][Full Text] [Related]
2. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
3. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
[TBL] [Abstract][Full Text] [Related]
4. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
Hitzel C; Koch N
Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
[TBL] [Abstract][Full Text] [Related]
5. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
Ghosh P; Amaya M; Mellins E; Wiley DC
Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
[TBL] [Abstract][Full Text] [Related]
6. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
Verreck FA; Fargeas CA; Hämmerling GJ
Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
[TBL] [Abstract][Full Text] [Related]
7. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
8. Evidence for invariant chain 85-101 (CLIP) binding in the antigen binding site of MHC class II molecules.
Bangia N; Watts TH
Int Immunol; 1995 Oct; 7(10):1585-91. PubMed ID: 8562503
[TBL] [Abstract][Full Text] [Related]
9. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of MHC class II I-Ab in complex with a human CLIP peptide: prediction of an I-Ab peptide-binding motif.
Zhu Y; Rudensky AY; Corper AL; Teyton L; Wilson IA
J Mol Biol; 2003 Feb; 326(4):1157-74. PubMed ID: 12589760
[TBL] [Abstract][Full Text] [Related]
11. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
12. Interference of distinct invariant chain regions with superantigen contact area and antigenic peptide binding groove of HLA-DR.
Vogt AB; Stern LJ; Amshoff C; Dobberstein B; Hämmerling GJ; Kropshofer H
J Immunol; 1995 Nov; 155(10):4757-65. PubMed ID: 7594477
[TBL] [Abstract][Full Text] [Related]
13. Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: a molecular dynamics simulation study.
Yaneva R; Springer S; Zacharias M
Biopolymers; 2009 Jan; 91(1):14-27. PubMed ID: 18767126
[TBL] [Abstract][Full Text] [Related]
14. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
[TBL] [Abstract][Full Text] [Related]
15. T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates.
Morkowski S; Goldrath AW; Eastman S; Ramachandra L; Freed DC; Whiteley P; Rudensky AYu
J Exp Med; 1995 Nov; 182(5):1403-13. PubMed ID: 7595211
[TBL] [Abstract][Full Text] [Related]
16. A continuous central motif of invariant chain peptides, CLIP, is essential for binding to various I-A MHC class II molecules.
Weenink SM; Milburn PJ; Gautam AM
Int Immunol; 1997 Feb; 9(2):317-25. PubMed ID: 9040013
[TBL] [Abstract][Full Text] [Related]
17. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
Denzin LK; Cresswell P
Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
[TBL] [Abstract][Full Text] [Related]
18. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
[TBL] [Abstract][Full Text] [Related]
19. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
20. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
Ramachandra L; Kovats S; Eastman S; Rudensky AY
J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
